Trial Profile
Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs Vincristine (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vitamin D
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Non-Hodgkin's lymphoma; Plasmablastic lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- Acronyms OPTIMAL>60
- 24 Apr 2024 Status changed from active, no longer recruiting to completed.
- 09 May 2023 Planned End Date changed from 1 May 2024 to 1 May 2025.
- 09 May 2023 Planned primary completion date changed from 1 Dec 2023 to 1 May 2025.